Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Zhu, Jiang ^a,b   He, Shiping ^a   Du, Jie ^a   Wang, Zhulin ^a   Li, Wang ^a   Chen, Xianxiong ^a   Jiang, Wenqi ^a,b   Zheng, Duo ^a   Jin, Guangyi ^a  

^a Shenzhen University School of Medicine   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Doxorubicin; Immunotherapy; Lymphoma; Toll like receptor 7

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 6; SZU 101; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENINE; MEMBRANE PROTEIN; SUCCINIC ACID DERIVATIVE; SZU-101; TLR7 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SYNTHESIS; EFFECTOR CELL; FLOW CYTOMETRY; HEK293 CELL LINE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE; TREATMENT DURATION; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; PATHOLOGY;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LYMPHOMA, T-CELL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; SUCCINATES; TOLL-LIKE RECEPTOR 7;

EID: 84925016356     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0121-9     Document Type: Article

References (27)

1. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203-16. doi:10.1016/j.beha.2011.02.009.
2. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949-64. doi:10.2217/imt.09.70.
3. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med. 2003;197(1):101-9.
4. Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun. 2003;71(6):3337-42.
5. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4∈+∈CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033-6. doi:10.1126/science.1078231.
6. Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunotherapy Cancer. 2014;2:12. doi:10.1186/2051-1426-2-12.
7. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A. 2003;100(11):6646-51. doi:10.1073/pnas.0631696100.
8. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009;146(3):282-91. doi:10.1111/j.1365-2141.2009.07773.x.
9. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol. 2006;80(2):192-8. doi:S0167-8140(06)00303-3.
10. Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121(2):251-9. doi:10.1182/blood-2012-05-432393.
11. Ehrke MJ, Verstovsek S, Krawczyk CM, Ujhazy P, Zaleskis G, Maccubbin DL, et al. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer. 1995;63(3):463-71.
12. Ehrke MJ, Verstovsek S, Ujhazy P, Meer JM, Eppolito C, Maccubbin DL, et al. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother. 1998;45(6):287-98.
13. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803-43.
14. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res. 2000;6(12):4950-6.
15. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27(2):190-9. doi:10.1038/sj.onc.1210913.
16. Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol. 2009;6(4):257-65. doi:10.3109/15476910903286733.
17. Liu HY, Hong YF, Huang CM, Chen CY, Huang TN, Hsueh YP. TLR7 negatively regulates dendrite outgrowth through the Myd88-c-Fos-IL-6 pathway. J Neurosci. 2013;33(28):11479-93. doi: 10.1523/JNEUROSCI. 5566-12.2013.
18. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007;13(23):7119-25. doi:10.1158/1078-0432.CCR-07-1443.
19. Akhter A, Masir N, Elyamany G, Phang KC, Mahe E, Al-Zahrani AM, et al. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system. J Neurooncol. 2015;121(2):289-96. doi:10.1007/s11060-014-1655-3.
20. Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006;20(2):286-95. doi:10.1038/sj.leu.2404061.
21. Smith TJ, Yamamoto K, Kurata M, Yukimori A, Suzuki S, Umeda S, et al. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol. 2010;89(3):284-90. doi:10.1016/j.yexmp.2010.08.003.
22. Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun K et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia. 2014. doi:10.1038/leu.2014.293
23. Lee SK, Chwee JY, Ma CA, Le Bert N, Huang CW, Gasser S. Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells. Clin Cancer Res. 2014;20(13):3485-95. doi:10.1158/1078-0432.CCR-13-2522.
24. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A. 2007;104(10):3990-5. doi:10.1073/pnas.0611624104.
25. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009;182(9):5217-24. doi:10.4049/jimmunol.0803826.
26. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, et al. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol. 2011;186(4):1963-9. doi:10.4049/jimmunol.1002320.
27. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol. 1983;105(1):20-3.